Since E. coli G3/10 is set out in a probiotic formulation that can be used for treatment of gastrointestinal disorders, MccS is very much likely to also be expressed effectively in vivo, rendering this beneficial microorganism a promising biological drug with prophylactic capacities against enteric pathogens such as Salmonella, Shigella or diarrheagenic E. coli. The gene discussed is HYAL2; the disease is digestive system disorder.